| Theme | Frontiers in Vitamin D Action | |
|---|---|---|
| Title | Pre-clinical and clinical effects of 1alpha,25-dihydroxy-22-oxavitamin D3 on bone diseases underlying chronic renal failure | |
| Publish Date | 2001/04 | |
| Author | Noboru Kubodera | Product Planning Dept. Chugai Parmaceutical Co., Ltd. |
| Author | Yoshiharu Yamada | Clinical Affairs Dept., Chugai Parmaceutical Co., Ltd. |
| [ Summary ] | Pre-clinical and clinical effects of 1alpha, 25dihydroxy-22-oxa-vitamin D3 (OCT), derived from the research to investigate potent biological characteristic of active vitamin D, 1α, 25-dihydroxyvitamin D3 on bone diseases underlying chronic renal failure have been described. OCT showed suppression of enhanced parathyroid hormone (PTH) secretion and ameliorated high-turnover bone and osteitis fibrosa in rats with slowly progressive nephritis. Intravenous administration of OCT also effectively suppressed PTH secretion and improved the bone histological characteristics of severe osteitis fibrosa in patients with severe secondary hyperparathyroidism. | |